Earnings summaries and quarterly performance for QUEST DIAGNOSTICS.
Executive leadership at QUEST DIAGNOSTICS.
James E. Davis
Detailed
Chief Executive Officer and President
CEO
CT
Catherine T. Doherty
Detailed
Executive Vice President, Regional Businesses
KK
Karthik Kuppusamy
Detailed
Senior Vice President, Clinical Solutions
ME
Michael E. Prevoznik
Detailed
Senior Vice President, General Counsel
SA
Sam A. Samad
Detailed
Executive Vice President, Chief Financial Officer
Board of directors at QUEST DIAGNOSTICS.
DM
Denise M. Morrison
Detailed
Director
GM
Gary M. Pfeiffer
Detailed
Director
LA
Luis A. Diaz, Jr., M.D.
Detailed
Director
RB
Robert B. Carter
Detailed
Director
TL
Timothy L. Main
Detailed
Director
TM
Timothy M. Ring
Detailed
Lead Independent Director
TC
Tracey C. Doi
Detailed
Director
VB
Vicky B. Gregg
Detailed
Director
WL
Wright L. Lassiter III
Detailed
Director
Research analysts who have asked questions during QUEST DIAGNOSTICS earnings calls.
Elizabeth Anderson
Evercore ISI
8 questions for DGX
Also covers: AGL, ALGN, CAH +23 more
EW
Erin Wright
Morgan Stanley
8 questions for DGX
Also covers: ALGN, BTSG, CAH +18 more
Jack Meehan
Nephron Research LLC
8 questions for DGX
Also covers: A, AVTR, BIO +17 more
Kevin Caliendo
UBS
8 questions for DGX
Also covers: AHCO, ALGN, AMWL +15 more
Patrick Donnelly
Citi
8 questions for DGX
Also covers: A, AVTR, BIO +22 more
Michael Cherny
Leerink Partners
7 questions for DGX
Also covers: ACCD, ALGN, CAH +18 more
AB
Andrew Brackmann
William Blair & Company, L.L.C.
6 questions for DGX
Also covers: ADPT, AWH, BDSX +11 more
David Westenberg
Piper Sandler
6 questions for DGX
Also covers: ADPT, AKYA, BLLN +13 more
Luke Sergott
Barclays
6 questions for DGX
Also covers: A, AVTR, BRKR +19 more
Michael Ryskin
Bank of America Merrill Lynch
6 questions for DGX
Also covers: A, ALGN, AVTR +28 more
PC
Pito Chickering
Deutsche Bank
6 questions for DGX
Also covers: ACHC, AHCO, AVAH +18 more
Tycho Peterson
Jefferies
5 questions for DGX
Also covers: A, AVTR, BIO +22 more
AB
Andrew Brackman
William Blair
2 questions for DGX
Also covers: BLLN, LH, VCYT
AH
Ann Hynes
Mizuho Financial Group
2 questions for DGX
Also covers: ARDT, BTSG, CI +18 more
Benjamin Shaver
Deutsche Bank AG
2 questions for DGX
Also covers: MD
EC
Eric Caldwell
Baird
2 questions for DGX
Noah Kava
Jefferies
2 questions for DGX
AD
Aaron David Izen
Bank of America
1 question for DGX
AK
Anna Krasinski
Barclays
1 question for DGX
EP
Eugene Park
Robert W. Baird & Co. Incorporated
1 question for DGX
Also covers: LH
LG
Lisa Gill
JPMorgan Chase & Co.
1 question for DGX
Also covers: AGL, CAH, CI +13 more
MH
Meghan Holtz
Jefferies Financial Group Inc.
1 question for DGX
Also covers: AHCO, AVAH, EHAB +4 more
MC
Michael Cherney
Jefferies Financial Group Inc.
1 question for DGX
Also covers: COR, LH
SD
Stephanie Davis
Barclays
1 question for DGX
Also covers: ACCD, CAH, COR +20 more
Recent press releases and 8-K filings for DGX.
Quest Diagnostics reports Q4 2025 results
DGX
Earnings
Guidance Update
- Quest Diagnostics reported Q4 2025 net revenues of $2.806 billion, up 7.1% year-over-year.
- Q4 2025 adjusted operating margin was 15.3%, down from 15.6% in Q4 2024.
- Q4 2025 adjusted diluted EPS was $2.42, an 8.5% increase year-over-year.
- Full-year 2026 guidance calls for revenues of $11.70 billion–$11.82 billion and adjusted diluted EPS of $10.50–$10.70.
2 days ago
Quest Diagnostics reports Q4 2025 results
DGX
Earnings
Guidance Update
New Projects/Investments
- Q4 consolidated revenues of $2.81 billion, up 7.1% year-over-year; organic revenue growth of 6.4% and requisition volumes up 8.5%.
- Full-year 2025 delivered double-digit growth in revenues and earnings per share.
- 2026 guidance: revenues of $11.7 billion–$11.82 billion (+6.0%–7.1%), adjusted EPS of $10.50–$10.70, and cash from operations of ~$1.75 billion.
- Co-lab solutions expected to generate $1 billion in annual revenues in 2026; partnership with Corewell Health will add $250 million of organic revenue at low single-digit margins.
- Consumer-initiated testing grew >20% in 2025, delivering ~$250 million in revenues; QuestHealth.com expanded to over 150 tests.
2 days ago
Quest Diagnostics reports Q4 2025 results
DGX
Earnings
Guidance Update
New Projects/Investments
- Q4 2025 revenues were $2.81 billion (+7.1% YoY; organic +6.4%), total volume +8.5%, with adjusted EPS of $2.42 (+8.5% YoY).
- 2025 full year delivered double-digit revenue and EPS growth; cash from operations was $1.89 billion.
- 2026 guidance: revenues of $11.7 billion–$11.82 billion (+6.0%–7.1%), adjusted EPS $10.50–$10.70, cash from operations ~ $1.75 billion, and capex ~ $550 million; operating margin is expected to expand.
- Strategic initiatives include scaling co-lab solutions with Corewell Health (targeting $1 billion in annual revenues in 2026) and growing consumer-initiated testing (nearly $250 million in 2025 via QuestHealth.com and wellness partnerships).
2 days ago
Quest Diagnostics reports Q4 2025 results and 2026 outlook
DGX
Earnings
Guidance Update
- Q4 2025 revenues were $2.81 billion, up 7.1% YoY, with organic revenue growth of 6.4%, and adjusted EPS of $2.42 (vs. $2.23 prior year).
- Full-year 2025 delivered double-digit growth in both revenues and EPS, driven by clinical innovations, strategic collaborations, and operational enhancements.
- 2026 guidance calls for revenues of $11.70 – $11.82 billion (6.0%–7.1% growth), adjusted EPS of $10.50 – $10.70, operating margin expansion, cash from operations of ~$1.75 billion, and CapEx of ~$550 million.
- Strategic initiatives include a one-year delay of PAMA rate cuts through end 2026, 3% cost savings via the Invigorate program, and expected $250 million in low-single-digit-margin co-lab revenues from Corewell Health in 2026.
2 days ago
Quest Diagnostics posts Q4 and FY 2025 results and 2026 guidance
DGX
Earnings
Guidance Update
- Q4 2025 revenues of $2.81 billion (+7.1% y/y); reported diluted EPS of $2.18 (+11.8% y/y) and adjusted diluted EPS of $2.42 (+8.5% y/y)
- FY 2025 net revenues of $11.04 billion (+11.8% y/y); reported diluted EPS of $8.75 (+13.8% y/y); adjusted diluted EPS of $9.85 (+10.3% y/y); cash from operations of $1.89 billion
- 2026 guidance: revenues of $11.70–11.82 billion, reported diluted EPS of $9.45–9.65, and adjusted diluted EPS of $10.50–10.70
3 days ago
Quest Diagnostics raises dividend to $0.86 per share and boosts buyback authorization
DGX
Dividends
Share Buyback
- Quest Diagnostics’ Board approved a 7.5% increase in its quarterly cash dividend to $0.86 per share (annualized $3.44), payable April 20, 2026, to shareholders of record April 6, 2026.
- The Board also increased its share repurchase authorization by $1 billion, adding to the roughly $0.4 billion available under the existing program as of December 31, 2025.
3 days ago
Quest Diagnostics outlines growth strategy at JPM Healthcare Conference
DGX
Guidance Update
M&A
- Quest Diagnostics expanded network access with Elevance and secured partnerships with large corporate physician groups to drive growth in hospital labs, reference testing, collaborative lab solutions and life sciences services.
- Consumer-initiated testing grew from $30 million in 2021 to a $250 million run rate by Q4, with QuestHealth.com contributing $100 million and channel partners (e.g., Function Health, Whoop) adding $150 million.
- Focused on advanced diagnostics—including cardiometabolic, autoimmune and brain health—with commercial launch of the AB4240 Alzheimer's blood-based test for amyloid and tau biomarkers.
- Reaffirmed 2026 guidance: 4–5% total revenue growth, 75–150 bps operating margin expansion, 7–9% adjusted EPS growth, and $3–3.3 billion free cash flow after capex.
Jan 13, 2026, 12:30 AM
Quest Diagnostics outlines growth strategy and guidance at JPMorgan Healthcare Conference
DGX
Guidance Update
M&A
- Tests one-third of U.S. adults, completing ~220 million requisitions and directly drawing blood for ~80 million individuals in 2024; network spans 8,000 sites and covers 90% of lives with 80 billion data points ( ).
- Prevention and wellness represent ~33% of revenue; consumer-initiated testing surged from $30 million in 2021 to a $250 million run rate in 2025, led by QuestHealth.com’s $100 million business ( ).
- Operates in a $90 billion laboratory market (~2% of a $5 trillion healthcare spend); targets 4–5% organic revenue growth, 75–150 bps margin expansion, 7–9% EPS growth, and $3–3.3 billion free cash flow (2025–27) with capital allocated to M&A, dividends, and share repurchases ( ).
- $2.8 billion deployed in M&A over three years—including the $1 billion LifeLabs Canada acquisition—and growing co-lab hospital services from $800 million toward a $1 billion target by 2026 ( ).
Jan 13, 2026, 12:30 AM
Quest Diagnostics presents at 44th Annual J.P. Morgan Healthcare Conference
DGX
Guidance Update
M&A
Revenue Acceleration/Inflection
- Quest Diagnostics tested one-third of the U.S. adult population in 2024 with 217 million requisitions and 80 million blood draws, covering 110 million unique patients across 8,000+ locations.
- Prevention and wellness represents ~1/3 of revenue, while the consumer business rose from $30 million in 2021 to a $250 million run rate in Q4 2025 via QuestHealth.com ($100 million) and channel partners ($150 million).
- The company reaffirmed its 2026 outlook: 4–5% revenue growth, 75–150 bps operating margin expansion, 7–9% adjusted EPS growth, and $3–3.3 billion free cash flow (2025–2027) targets.
- Key investments include AI/automation (end-to-end lab systems, digital cytology), $2.8 billion in M&A (2023–25), and Project Nova to modernize the order-to-cash infrastructure.
Jan 13, 2026, 12:30 AM
Quest Diagnostics completes Michigan lab joint venture
DGX
M&A
New Projects/Investments
- Quest Diagnostics and Corewell Health complete laboratory services joint venture, Diagnostic Lab of Michigan, LLC, with Quest owning 51% and Corewell Health 49%
- Existing Quest and Corewell laboratories will continue providing services until a new 100,000-square-foot facility opens in Q1 2027
- Quest begins deploying Co-Lab Solutions across 21 Corewell Health hospitals, including supply chain, lab management, patient blood and anemia management, and lab analytics and stewardship
Jan 5, 2026, 1:58 PM
Quarterly earnings call transcripts for QUEST DIAGNOSTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more